Trial Profile

BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BCMA CD19 cCAR T-cell therapy-iCell Gene Therapeutics (Primary)
Indications Lymphoma; Multiple myeloma
Focus Adverse reactions; First in man
Sponsors iCell Gene Therapeutics

Most Recent Events

21 Nov 2019 New trial record
14 Nov 2019 According to an iCell Gene Therapeutics media release, data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.
13 Nov 2019 Trial dessign published in the Blood

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com